ATE312176T1 - Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien - Google Patents

Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien

Info

Publication number
ATE312176T1
ATE312176T1 AT01927769T AT01927769T ATE312176T1 AT E312176 T1 ATE312176 T1 AT E312176T1 AT 01927769 T AT01927769 T AT 01927769T AT 01927769 T AT01927769 T AT 01927769T AT E312176 T1 ATE312176 T1 AT E312176T1
Authority
AT
Austria
Prior art keywords
factor viii
human cell
production
blood clotting
muteins
Prior art date
Application number
AT01927769T
Other languages
English (en)
Inventor
Charlotte Hauser
Andrea Hoerster
Carola Schroeder
Michael Lehnerer
Original Assignee
Octagene Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/de
Application filed by Octagene Gmbh filed Critical Octagene Gmbh
Application granted granted Critical
Publication of ATE312176T1 publication Critical patent/ATE312176T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01927769T 2000-03-22 2001-03-21 Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien ATE312176T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (de) 2000-03-22 2000-03-22 Herstellung von rekombinanten Blutgerinnungsfaktoren in humanen Zellinien
US20324900P 2000-05-08 2000-05-08
PCT/EP2001/003220 WO2001070968A2 (en) 2000-03-22 2001-03-21 Production of recombinant blood clotting factors in human cell lines

Publications (1)

Publication Number Publication Date
ATE312176T1 true ATE312176T1 (de) 2005-12-15

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927769T ATE312176T1 (de) 2000-03-22 2001-03-21 Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien

Country Status (28)

Country Link
US (1) US7572619B2 (de)
EP (2) EP1460131A3 (de)
JP (1) JP3894795B2 (de)
KR (1) KR100581574B1 (de)
CN (1) CN1454257B (de)
AT (1) ATE312176T1 (de)
AU (3) AU2001254715B2 (de)
BE (1) BE2014C077I2 (de)
BG (1) BG65930B1 (de)
BR (1) BRPI0109494B8 (de)
CA (1) CA2404163C (de)
CZ (1) CZ303929B6 (de)
DE (1) DE60115613T2 (de)
DK (1) DK1266006T3 (de)
EA (1) EA004317B1 (de)
EE (1) EE200200538A (de)
ES (1) ES2254403T3 (de)
FR (1) FR15C0003I2 (de)
HR (1) HRP20020767B1 (de)
HU (1) HU228091B1 (de)
IL (2) IL151857A0 (de)
MX (1) MXPA02009221A (de)
NO (1) NO330910B1 (de)
NZ (1) NZ521732A (de)
RS (1) RS50743B (de)
SI (1) SI1266006T1 (de)
SK (1) SK287706B6 (de)
WO (1) WO2001070968A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1266006T3 (da) * 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1469064A1 (de) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression von Proteinen in endothelialen Zellen, die von Vorläuferzellen aus Nabelschnurblut abgeleitet wurden
WO2005094873A1 (en) * 2004-03-19 2005-10-13 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
ES2436741T3 (es) 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP5523674B2 (ja) * 2005-02-11 2014-06-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 植物タンパク質加水分解産物を含有する血清フリーの細胞培養液におけるポリペプチドの生産
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
AU2008245524A1 (en) * 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
WO2009028575A1 (ja) * 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固第vii因子プロモーターの活性化剤及びその利用
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
DK2482841T4 (da) 2009-10-02 2022-10-24 Childrens Hospital Philadelphia Sammensætninger og fremgangsmåder til at forbedre koagulationsfaktor-viii-funktion
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
RU2600886C2 (ru) 2011-05-13 2016-10-27 Октафарма Аг Способ повышения продуктивности эукариотических клеток в продуцировании рекомбинантного fviii
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素-n-硫酸酯酶之方法
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
EP3330283A3 (de) 2012-03-16 2018-07-11 Albumedix A/S Albuminvarianten
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
EP2948168B1 (de) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Hemmung eines gewebefaktorpfad-inhibitors mit faktor xa-derivaten
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
EP2853538A1 (de) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analoge von Temporin-SHa und Verwendungen davon
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
CN106687128B (zh) 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
EP3394098A4 (de) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin-antikörper und verfahren zur verwendung
PE20181922A1 (es) 2016-04-15 2018-12-11 Univ Pennsylvania Terapia genica para tratar la hemofilia a
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3625329A1 (de) 2017-05-17 2020-03-25 Octapharma AG Verfahren zur herstellung eines rekombinanten zielproteins
EP4640703A3 (de) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s-antikörper und verfahren zur verwendung
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP3870206A4 (de) 2018-10-23 2023-04-26 The Children's Hospital Of Philadelphia Zusammensetzungen und verfahren zur modulation der faktor-viii-funktion
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
CA3221235A1 (en) 2021-06-11 2022-12-15 Ali Ladram Short antimicrobial peptides
CN116590262A (zh) * 2023-03-23 2023-08-15 上海交通大学医学院附属瑞金医院 一种凝血因子ix突变体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
WO1986006408A1 (en) 1985-04-22 1986-11-06 Genetics Institute, Inc. HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX
ATE87663T1 (de) * 1986-01-03 1993-04-15 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
DE69032043T2 (de) * 1989-11-17 1998-06-04 Chiron Corp Proteinkomplexe mit faktor viii:c-aktivität und deren herstellung
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
FI923347A0 (fi) 1990-01-26 1992-07-23 Immuno Ag Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
WO1998000542A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
AU780854B2 (en) * 1999-02-19 2005-04-21 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
WO2001012836A1 (en) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof
DK1266006T3 (da) * 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Also Published As

Publication number Publication date
AU2001254715B2 (en) 2006-02-02
NO20024475L (no) 2002-11-20
EP1460131A2 (de) 2004-09-22
BRPI0109494B8 (pt) 2021-05-25
AU2006201848A1 (en) 2006-05-25
FR15C0003I2 (fr) 2015-11-20
HUP0300588A2 (hu) 2003-06-28
BRPI0109494B1 (pt) 2021-05-11
BE2014C077I2 (de) 2020-01-30
EP1266006B1 (de) 2005-12-07
IL151857A (en) 2010-05-31
ES2254403T3 (es) 2006-06-16
BR0109494A (pt) 2002-12-10
KR20030011079A (ko) 2003-02-06
HRP20020767A2 (en) 2005-02-28
US20040023333A1 (en) 2004-02-05
AU5471501A (en) 2001-10-03
BG107152A (bg) 2003-06-30
CA2404163A1 (en) 2001-09-27
NO330910B1 (no) 2011-08-15
HU228091B1 (en) 2012-10-29
CZ20023166A3 (cs) 2003-02-12
YU71002A (sh) 2005-11-28
EP1266006A2 (de) 2002-12-18
EP1460131A3 (de) 2005-06-01
HRP20020767B1 (hr) 2011-09-30
RS50743B (sr) 2010-08-31
EA004317B1 (ru) 2004-02-26
US7572619B2 (en) 2009-08-11
CA2404163C (en) 2009-09-29
DE60115613T2 (de) 2006-08-24
SK287706B6 (en) 2011-07-06
NO20024475D0 (no) 2002-09-19
FR15C0003I1 (fr) 2015-02-27
JP2003530093A (ja) 2003-10-14
CN1454257A (zh) 2003-11-05
MXPA02009221A (es) 2005-07-25
DK1266006T3 (da) 2006-01-16
JP3894795B2 (ja) 2007-03-22
CN1454257B (zh) 2013-01-16
KR100581574B1 (ko) 2006-05-22
WO2001070968A2 (en) 2001-09-27
EE200200538A (et) 2004-04-15
WO2001070968A3 (en) 2001-12-13
NZ521732A (en) 2004-05-28
SK15042002A3 (sk) 2003-09-11
CZ303929B6 (cs) 2013-07-03
IL151857A0 (en) 2003-04-10
SI1266006T1 (sl) 2006-06-30
BG65930B1 (bg) 2010-05-31
DE60115613D1 (de) 2006-01-12
EA200201008A1 (ru) 2003-02-27
HUP0300588A3 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
DE60115613D1 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE437221T1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
EE05075B1 (et) POL1212 aminohappej„rjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappej„rjestust omava valgu valmistamiseks
ATE532858T1 (de) Menschliche gerinnungsfaktor-vii-polypeptide
AU2001254624A1 (en) Human coagulation factor vii variants
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE465266T1 (de) Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
DE69434689D1 (de) Adenovirale vektoren für die behandlung der hämophilie
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE602004028239D1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
DE69027967D1 (de) Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen
EP1679372A4 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
ATE452139T1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1266006

Country of ref document: EP

EEFA Change of the company name